Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ETX 018810 (Primary)
  • Indications Neuropathic pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eliem Therapeutics

    • Most Recent Events

    • 02 Aug 2022 According to an Eliem Therapeutics media release, based on results from this trial and NCT04688671 trial the company has decided to discontinue development of ETX-810.
    • 02 Aug 2022 Primary endpoint has not been met. (Change from baseline to Week 4 in the weekly average of the daily pain score), according to an Eliem Therapeutics media release.
    • 02 Aug 2022 Results presented in the Eliem Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top